Document is current
Any future updates will be listed below
-
Authors
Conti, Alberto G. https://orcid.org/0000-0003-0725-337X
Evans, Alexander C. https://orcid.org/0000-0002-6363-2684
von Linde, Teresa https://orcid.org/0009-0007-4876-659X
Deguit, Christian Deo T.
Whiteside, Sarah K.
Wesolowski, Alexander J.
Imianowski, Charlotte J. https://orcid.org/0000-0002-7116-7591
Yamashita-Kanemaru, Yumi https://orcid.org/0000-0002-2475-8858
Dahmani, Layla https://orcid.org/0009-0003-1069-2370
Chapman, Jack https://orcid.org/0009-0008-6686-8271
Pillay, Ardon M. https://orcid.org/0009-0004-2741-2600
Al-Deka, Aws
Greaves, Randy
Burton, Oliver
Vardaka, Panagiota https://orcid.org/0000-0002-1253-243X
Sampurno, Shienny
Pérez-Núñez, Iván
Saw, Nicole Y. L.
Yang, Jie https://orcid.org/0000-0001-9157-0532
Howden, Andrew J. M. https://orcid.org/0000-0002-4332-9469
Okkenhaug, Klaus https://orcid.org/0000-0002-9432-4051
Mitra, Suman https://orcid.org/0000-0002-3426-371X
Swiatczak, Bartlomiej https://orcid.org/0000-0001-6767-3064
Parish, Ian A. https://orcid.org/0000-0003-3528-478X
Roychoudhuri, Rahul https://orcid.org/0000-0002-5392-1853
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/X006344/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/Z516132/1)
European Commission (EP/X024709/1)
RCUK | Medical Research Council (MR/Y013301/1)
RCUK | Medical Research Council (MR/W018454/1)
European Commission refers to an ERC consolidator award
CRUK Cambridge Centre PhD Studentship
Fondation ARC pour la Recherche sur le Cancer (programmes labellises (PGA))
Australian Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 3 December 2025
First Online: 16 January 2026
Competing interests
: A.G.C., A.C.E. and R.R. are named inventors on a provisional patent related to this work and are shareholders in Alceus Biosciences. R.R. is a Scientific Advisor for Enhanc3D Genomics and OligoTune and holds industrially funded collaborations with AstraZeneca and F-Star Therapeutics on topics unrelated to this study. I.A.P. has received research funding from AstraZeneca, Bristol Myers Squibb and Roche Genentech on topics unrelated to this study. The other authors declare no competing interests.
